Indian Pharmacopoeia Commission Signs MoUs to Strengthen Drug Quality and Patient Safety Framework

New Delhi, April 24, 2026: The Indian Pharmacopoeia Commission under the Ministry of Health and Family Welfare has entered into key agreements with the Pharmaceuticals and Medical Devices Bureau of India and the National Institute of Pharmaceutical Education and Research Hajipur to enhance drug quality standards, promote research, and improve patient safety across the country.

The agreement with the Pharmaceuticals and Medical Devices Bureau of India focuses on strengthening quality checks for medicines distributed through Jan Aushadhi Kendras. Under this arrangement, selected medicine batches may be tested to ensure quality standards. The initiative also promotes the use of the National Formulary of India to encourage responsible and effective use of medicines. Efforts will be made to expand awareness of drug safety reporting through helpline services and digital tools, along with training programmes for pharmacists and stakeholders.

The second agreement with the National Institute of Pharmaceutical Education and Research Hajipur aims to advance pharmaceutical research and scientific collaboration. The partnership will focus on areas such as impurity analysis, development of testing methods, and strengthening standards for biologics, biosimilars, and advanced therapies including cell and gene based treatments.

Both institutions will work together on academic exchange, training sessions, workshops, and research publications. Opportunities for students and researchers through internships and fellowships will also be expanded to build capacity in pharmaceutical sciences.

Officials stated that these collaborations are expected to enhance India’s healthcare system by ensuring high quality medicines, improving patient safety measures, and encouraging innovation in pharmaceutical research and regulation.